GlaxoSmithKline in Agreement to Acquire Human Genome Sciences

Cleary Gottlieb represented GlaxoSmithKline in connection with its unsolicited tender offer to acquire Human Genome Sciences and the subsequent negotiated acquisition of HGS for approximately $3.6 billion on an equity basis.

GSK is one of the world’s leading research-based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. HGS is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease.